Related Experiment Video
Updated: Jul 11, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Intravenous thrombolysis for acute ischemic stroke: the phase IV data
David Tanne1, Andrew M Demchuk, Scott E Kasner
1Acute Stroke Unit, Department of Neurology, Chaim Sheba Medical Center and, Sackler Faculty of Medicine, Tel Aviv University, Israel. tanne@post.tau.ac.il
The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial showed intravenous tissue plasminogen activator (t-PA) can be effective for acute ischemic stroke. Proper use, careful patient selection, and adherence to guidelines are crucial for maximizing benefits and minimizing risks.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Emergency Medicine
Background:
- The 1995 NINDS rt-PA Stroke Trial offered hope for acute ischemic stroke treatment but raised questions about real-world applicability.
- Postmarketing studies indicate intravenous t-PA can achieve good outcomes with low complications when used correctly.
- However, preliminary data suggest variable t-PA applicability and potential risks outweighing benefits in certain situations.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous tissue plasminogen activator (t-PA) in routine clinical practice for acute ischemic stroke.
- To assess the generalizability of the NINDS rt-PA Stroke Trial findings to diverse clinical settings.
- To identify factors influencing the successful application and outcomes of thrombolytic therapy in stroke patients.
Main Methods:
- Analysis of data from multiple postmarketing studies and systemic audits of t-PA use.
- Review of patient selection criteria and treatment adherence to established guidelines.
- Evaluation of door-to-needle times and their impact on treatment effectiveness.
Main Results:
- Consistent achievement of favorable outcomes and low complication rates with appropriate t-PA administration.
- Uncertainty regarding the broad applicability of t-PA, with potential risks in specific patient groups.
- Door-to-needle times frequently exceeding the recommended 60-minute goal.
- Growing proportion of effectively treated patients with increased experience and improved organizational strategies.
Conclusions:
- The NINDS rt-PA Stroke Trial protocol remains the standard of care for acute ischemic stroke.
- Strict adherence to treatment guidelines, careful patient selection, and experienced physician use are paramount for safe and effective t-PA therapy.
- While significant progress has been made, further optimization is needed to maximize benefits for all stroke victims, potentially aided by advanced neuroimaging techniques.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Venous Thrombosis IV: Nursing Management

